Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $62.78 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Bernstein SocGen Group Starts Amphenol (APH) at Outperform
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion